New CAR-T therapy targets tough lymphoma in early trial

NCT ID NCT05784441

Ongoing Disease control Sponsor: Janssen Research & Development, LLC Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 31, 2026 · Updated 2 times

Summary

This early-phase trial is testing a new treatment called JNJ-90009530, a type of CAR-T cell therapy that targets a protein called CD20 on lymphoma cells. The study includes 21 adults with relapsed or refractory B-cell non-Hodgkin lymphoma who have already tried other treatments. The main goals are to find a safe dose and see if the therapy can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: JNJ-90009530 (a CAR-T cell therapy targeting CD20)
What this could lead to: If successful, this could provide a new treatment option for patients with hard-to-treat lymphoma who have run out of standard therapies.
What could go wrong: This is a very early (phase 1b) and small (21 participants) study focused on safety and dosing. It may not lead to a widely available treatment, and CAR-T therapies carry risks like severe immune reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY B CELL NON HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell neoplasm B-cell non-Hodgkin lymphoma Recurrence relapsed/refractory diffuse large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RELAPSED OR REFRACTORY B CELL NON HODGKIN LYMPHOMA

Contacts and locations

Locations

Austin Hospital

Heidelberg, 3084, Australia
Hadassah Medical Center

Jerusalem, 9112001, Israel
MD Anderson Cancer Center

Houston, Texas, 77030, United States
Mayo Clinic Rochester

Rochester, Minnesota, 55905, United States
Monash Medical Centre

Clayton, 3168, Australia
Royal Brisbane and Women's Hospital

Herston, 4029, Australia
Royal Prince Alfred Hospital

Camperdown, 2050, Australia
Rutgers University

New Brunswick, New Jersey, 08901, United States
Sheba Medical Center

Ramat Gan, 5266202, Israel
University College London Hospitals

London, NW1 2BU, United Kingdom
University Hospitals Cleveland Medical Center

Cleveland, Ohio, 44106, United States
University of Iowa Hospital

Iowa City, Iowa, 52242, United States
University of Kentucky

Lexington, Kentucky, 40506, United States
University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States
Westmead Hospital

Westmead, 2145, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.